CTOs on the Move

Areteia Therapeutics

www.areteiatx.com

 
Areteia Therapeutics (areteiatx.com) is a clinical stage biotechnology company committed to putting asthma patients in better control of their disease and lives by developing the first potential oral drug for eosinophilic asthma. Areteia`s lead drug candidate is dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences. A syndicate of leading life sciences and strategic investors led by Bain Capital Life Sciences with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners, has committed to invest up to $350 million in Series A financing to ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.areteiatx.com
  • 12770 High Bluff Drive Suite 380
    San Diego, CA USA 92130
  • Phone: 858.987.4278

Executives

Name Title Contact Details

Similar Companies

Protox Therapeutics Inc

Protox Therapeutics Inc is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VBI Vaccines

VBI Vaccines Inc.is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology.

Drugstore Pharmacy

Drugstore Pharmacy is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bioanalytical Systems

BASi provides world-class research to the pharmaceutical industry worldwide. Established in 1974, we offer an extensive array of contract laboratory services and also manufacture more than 30 different scientific instruments. At BASi we focus on developing innovative services and products that increase efficiency and reduce costs associated with taking new drugs to market.

Deep Genomics

Our founding belief is that the future of medicine will rely on artificial intelligence, because biology is too complex for humans to understand. Today, the molecular world of the cell can be experimentally interrogated like never before. The resulting datasets provide an unprecedented opportunity to build artificial intelligence systems that are biologically accurate and that support the detection of disease and the development of molecular interventions. Deep Genomics is building a biologically accurate data- and AI-driven platform that supports geneticists, molecular biologists and chemists in the development of therapies. Over the next two years, Deep Genomics will use its platform to unlock new classes of antisense oligonucleotide therapies that were previously inaccessible or out of reach, and advance them for clinical evaluation. In project Saturn, the platform will be used to search across a vast space of over 69 billion molecules with the goal of generating a library of 1000 compounds that can be used to manipulate cell biology and design therapies.